United States - English - NLM (National Library of Medicine)

cangene biopharma inc. - human hepatitis b virus immune globulin (unii: xii270yc6m) (human hepatitis b virus immune globulin - unii:xii270yc6m) - human hepatitis b virus immune globulin 312 [iu] in 1 ml

United States - English - NLM (National Library of Medicine)

cangene biopharma, llc - human hepatitis b virus immune globulin (unii: xii270yc6m) (human hepatitis b virus immune globulin - unii:xii270yc6m) - human hepatitis b virus immune globulin 50 mg in 1 ml

United States - English - NLM (National Library of Medicine)

grifols usa, llc - human hepatitis b virus immune globulin (unii: xii270yc6m) (human hepatitis b virus immune globulin - unii:xii270yc6m) - human hepatitis b virus immune globulin 220 [iu] in 1 ml - recommendations on post-exposure prophylaxis are based on available efficacy data and on the likelihood of future hbv exposure for the person requiring treatment. in all exposures, a regimen combining hepatitis b immune globulin (human) with hepatitis b vaccine will provide both short- and long-term protection, will be less costly than the two-dose hepatitis b immune globulin (human) treatment alone, and is the treatment of choice.(9) hyperhep b  is indicated for post-exposure prophylaxis in the following situations: after either parenteral exposure, e.g., by accidental “needlestick” or direct mucous membrane contact (accidental splash), or oral ingestion (pipetting accident) involving hbsag-positive materials such as blood, plasma or serum. for inadvertent percutaneous exposure, a regimen of two doses of hepatitis b immune globulin (human), one given after exposure and one a month later, is about 75% effective in preventing hepatitis b in this setting. infants born to hbsag-positive mothers are at risk of be

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

biotest (uk) ltd - hepatitis b immunoglobulin human - solution for infusion - 50unit/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

biotest (uk) ltd - hepatitis b immunoglobulin human - solution for infusion - 50unit/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

biotest (uk) ltd - hepatitis b immunoglobulin human - solution for infusion - 50unit/1ml

Canada - English - Health Canada

cutter med & biol, division of miles canada ltd. - hepatitis b immunoglobulin (human) - liquid - nil - hepatitis b immunoglobulin (human) nil - serums

New Zealand - English - Medsafe (Medicines Safety Authority)

csl behring (nz) ltd - tetanus immunoglobulin, human 250 [iu] (immunoglobulin ex nz =160mg/ml) - solution for injection - 250 iu - active: tetanus immunoglobulin, human 250 [iu] (immunoglobulin ex nz =160mg/ml) excipient: glycine - tetanus immunoglobulin-vf is indicated for the passive protection of individuals who have sustained a tetanus-prone wound and who have either not been actively immunised against tetanus or whose immunisation history is doubtful. it should also be given to the fully immunised patient with a tetanus-prone wound if more than 10 years have elapsed since the last vaccine dose. in all the above instances, active immunisation with a tetanus vaccine should be commenced at the same time according to current datasheet recommendations.

Malta - English - Medicines Authority

bio products laboratory limited - anti, d immunoglobulin, human - solution for injection - anti-d immunoglobulin, human 250 international unit(s)/millilitre - immune sera and immunoglobulins

Singapore - English - HSA (Health Sciences Authority)

eshcol pharmaceutical group singapore pte ltd - human hepatitis b immunoglobulin in 150g/l human plasma protein (igg ≥ 96%) - injection - 500 iu/ml - human hepatitis b immunoglobulin in 150g/l human plasma protein (igg ≥ 96%) 500 iu/ml